Skip to main content
. Author manuscript; available in PMC: 2023 Aug 19.
Published in final edited form as: ACS Chem Biol. 2022 Jul 14;17(8):2188–2200. doi: 10.1021/acschembio.2c00330

Figure 6. Top molecules reported to enhance human oligodendrocyte formation inhibit EBP, CYP51, and S14R in human GBM528 cells.

Figure 6.

(A) Validated screening hits from Li et al. 2022 with annotations of subsequently-established inhibitory activity for EBP, CYP51, or sterol 14-reductase. (B), (E), (F) GC-MS based quantification of zymostenol and zymosterol levels in GBM528 cells treated for 24 h with the indicated screening hits at 10 μM. (C) GC-MS based quantification of lanosterol levels in GBM528 cells treated for 24 h with clotrimazole at 10μM. (D), (G) GC-MS based quantification of 14-dehydrozymostenol levels in GBM528 cells treated for 24 h with the indicated molecules at 10 μM. n=2 wells per condition. (H) Percentage of MBP+ oligodendrocytes generated from OPCs following treatment with bioactive small molecules in dose response as shown. n=4 wells per condition, except DMSO and amorolfine, n=8 wells with >1,000 cells analyzed per well.